Equities
Health CareMedical Equipment and Services
  • Price (USD)147.66
  • Today's Change-0.34 / -0.23%
  • Shares traded701.76k
  • 1 Year change+113.66%
  • Beta1.9526
Data delayed at least 15 minutes, as of Mar 04 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

  • Revenue in USD (TTM)605.49m
  • Net income in USD188.99m
  • Incorporated2018
  • Employees898.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Haemonetics Corp1.32bn175.44m3.05bn3.02k18.033.3710.592.313.643.6427.4019.460.5251.586.47436,081.706.995.418.306.5559.3253.2013.319.181.1512.690.57330.003.956.6042.6416.994.37--
ICU Medical Inc2.23bn732.00k3.52bn13.00k5,780.391.6617.221.580.02470.024790.5086.030.54062.3512.28171,635.500.0465-0.65180.0534-0.737636.8434.160.0861-1.111.151.700.378---6.3311.91100.62-61.53-0.6816--
LivaNova PLC1.39bn-242.47m3.74bn3.30k--3.12--2.70-4.47-4.4725.3721.960.5432.846.79420,622.10-9.48-3.21-12.39-3.9768.0468.27-17.46-6.551.163.670.2389--10.748.24-483.45--18.27--
iRhythm Holdings, Inc747.14m-44.55m4.07bn2.40k--26.61--5.44-1.41-1.4123.354.730.765712.339.60311,307.50-4.57-16.40-5.28-19.6570.5768.67-5.96-19.444.48--0.8096--26.2423.0260.67--27.88--
Merit Medical Systems Inc1.52bn128.49m4.45bn7.50k35.212.8117.462.932.132.1325.0726.660.5942.437.70202,120.805.034.565.535.1048.7046.738.487.342.9516.770.31660.0011.759.486.76--11.48--
Stevanato Group SpA1.36bn163.27m4.46bn5.52k24.622.4117.133.280.59820.59824.986.120.50582.952.65246,184.706.088.027.6310.9429.2731.0112.0113.241.3030.000.23866.821.7215.53-19.1324.6133.52--
Envista Holdings Corp2.72bn47.00m4.70bn12.00k104.271.5128.821.730.2750.27516.1018.960.49314.626.86226,625.000.8523-2.141.01-2.5855.0256.701.73-5.212.046.700.318--8.327.11104.202.03-1.03--
TransMedics Group Inc605.49m188.99m5.08bn898.0031.0910.7223.468.384.764.7914.9413.810.64675.096.65674,269.5020.194.7521.935.1859.9261.2731.218.526.5984.700.51990.0037.1388.21436.58--164.81--
Lantheus Holdings Inc1.54bn233.56m5.09bn1.19k23.454.6716.773.303.363.3622.3316.870.73289.044.531,292,212.0011.1011.2612.8512.9861.1061.6115.1514.472.51--0.34320.000.501935.35-25.25--23.67--
Teleflex Inc2.39bn58.53m5.40bn15.50k98.551.7322.862.261.24-20.5653.5970.700.3412.235.95154,489.000.83353.120.92663.4353.1357.052.4410.062.012.730.458128.4817.25-4.722.34-29.490.98210.00
Caris Life Sciences Inc-100.00bn-100.00bn5.47bn----11.43----------1.70------------------------9.36--0.4404--34.67--18.22------
Bruker Corp3.44bn-22.50m5.98bn11.09k--2.4330.021.74-0.1485-0.148522.6316.150.57051.645.22310,013.50-0.12125.07-0.15536.7647.1349.70-0.21247.560.85539.300.426813.192.0811.57-119.89--4.344.56
Avantor Inc6.55bn-530.20m5.99bn13.50k--1.08--0.914-0.7775-0.77759.628.160.54815.706.21485,348.20-4.442.78-5.173.1832.6533.77-8.095.001.183.620.41490.00-3.410.4913-174.52--15.90--
Glaukos Corp507.44m-187.69m6.84bn1.09k--10.32--13.48-3.27-3.278.8711.410.54321.845.99463,840.90-20.09-12.56-22.19-13.5577.9776.60-36.99-34.644.06--0.094--32.3317.67-28.23--28.47--
Repligen Corp738.26m48.89m6.93bn2.00k142.383.2954.319.390.86430.864313.0537.390.25552.235.04369,128.001.692.881.773.2052.6553.586.6210.737.12--0.20470.0016.3615.05291.64-3.99-0.4706--
Data as of Mar 04 2026. Currency figures normalised to Transmedics Group Inc's reporting currency: US Dollar USD

Institutional shareholders

53.37%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 20254.81m14.11%
Fidelity Management & Research Co. LLCas of 31 Dec 20254.47m13.11%
The Vanguard Group, Inc.as of 31 Dec 20253.32m9.75%
SSgA Funds Management, Inc.as of 31 Dec 20251.28m3.74%
Nomura Investment Management Business Trustas of 31 Dec 2025832.24k2.44%
Geode Capital Management LLCas of 31 Dec 2025816.47k2.40%
Driehaus Capital Management LLCas of 31 Dec 2025712.04k2.09%
Hood River Capital Management LLCas of 31 Dec 2025690.36k2.03%
Goldman Sachs Asset Management LPas of 31 Dec 2025659.86k1.94%
FIAM LLCas of 31 Dec 2025609.00k1.79%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.